Tetzlaff, Kay
Boehringer Ingelheim (Germany) · University of Tübingen
3 papers on CoChatORCID 0000-0003-1411-7640
Most cited papers
- Verified
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases
Cited by 2,403
- Verified
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine
Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Cited by 1,647
- Verified
The natural history of progressive fibrosing interstitial lung diseases
Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases
Cited by 293
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free